This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
SUMMARY
- The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
- MANHATTAN, an ambispective observational cohort study, compared the effectiveness, persistence, and tolerability of second-line subcutaneous (SC) TREMFYA versus vs SC tumor necrosis factor inhibitors (TNFis) in adult patients with psoriatic arthritis (PsA) after a first-line TNFi. Results are available through week (W) 52.1,2
- Results from a real-world retrospective study comparing the on-label treatment persistence in adult patients with PsA treated with SC TREMFYA vs SC TNFis using the IQVIATM database are summarized below.3,4
- A Bayesian network meta-analysis (NMA) indirectly compared the treatment effect of SC TREMFYA to other targeted therapies, including TNFis (Intravenous (IV): golimumab, infliximab, adalimumab, etanercept, and certolizumab pegol), on joint and skin efficacy outcomes and safety in adults with active PsA.5,6
CLINICAL DATA
Ambispective Studies
MANHATTAN Study
González-Molina et al (2025)1 evaluated the effectiveness, persistence, and tolerability of second-line SC TREMFYA compared with second-line SC TNFis in adults with PsA who have experienced treatment failure with a prior first-line SC TNFi in an ambispective observational cohort study. Results are available through week 52.
Study Design/Methods
- This study is conducted across 37 Spanish centers; an interim analysis evaluated the effectiveness and tolerability through week 52.
- The following study endpoints have been included:
- Percentage of patients achieving minimal disease activity (MDA)
- Percentage of patients achieving low disease activity (LDA) or remission per the Disease Activity in Psoriatic Arthritis (DAPSA) score
- Presence of dactylitis and enthesitis measured by the Leeds Enthesitis Index (LEI)
- Health assessment questionnaire (HAQ)
- Mean changes in the tender joint count (TJC) and swollen joint count (SJC)
- Adverse events (AEs) and drug-related AEs were recorded.
- The study design and visit schedule are summarized in Figure: MANHATTAN Study Design and Visit Schedule.
MANHATTAN Study Design and Visit Schedule1

Abbreviations: GUS, guselkumab; TNFi, tumor necrosis factor inhibitor; W, week.
Results
Baseline Characteristics
- A total of 175 patients (TREMFYA, n=98; TNFi, n=77) were analyzed in the interim analysis. For baseline characteristics, see Table: Selected Baseline Characteristics.
Selected Baseline Characteristics1
|
|
|
|---|
Female, n (%)
| 59 (60.2)
| 41 (53.2)
|
BMI (kg/m2), mean (SD)
| 28.1 (6.3)
| 26.6 (5.5)
|
Age at PsA diagnosis (years), mean (SD)
| 44.8 (11.7)
| 44.2 (11.9)
|
PsA characteristics
|
Active PsO, n (%)
| 66 (67.3)
| 34 (44.2)
|
Dactylitis, n (%)
| 15 (15.5) (n=97)
| 14 (18.2) (n=77)
|
Enthesitis, n (%)
| 21 (21.6) (n=97)
| 28 (36.4) (n=77)
|
TJC, mean (SD)
| 6.1 (7.0) (n=74)
| 5.2 (5.4) (n=65)
|
SJC, mean (SD)
| 3.3 (4.5) (n=74)
| 2.7 (3.8) (n=65)
|
DAPSA, mean (SD)
| 22.9 (13.4) (n=64)
| 21.4 (11.5) (n=51)
|
BSA, mean (SD)
| 4.3 (6.8) (n=60)
| 2.3 (5.0) (n=40)
|
Most common first-line TNFi, n (%)
| Adalimumab 71 (72.4)
| Adalimumab 50 (64.9)
|
Most common second-line TNFi, n (%)
| NA
| Etanercept 31 (40.3)
|
Concomitant conventional DMARDs, n (%)
| 42 (42.9)
| 34 (44.2)
|
Abbreviations: BMI, body mass index; BSA, body surface area; DAPSA, Disease Activity in Psoriatic Arthritis; DMARD, disease-modifying antirheumatic drug; NA, not applicable; PsA, psoriatic arthritis; PsO, psoriasis; SD, standard deviation; SJC, swollen joint count; TJC, tender joint count; TNFi, tumor necrosis factor inhibitor.
|
Effectiveness and Tolerability of TREMFYA and TNFi at Week 52
- TJC improved in both groups, with a mean absolute change from baseline of -2.4 at week 12 and -3.1 at week 52 in the TREMFYA group and of -1.5 at week 12 and -3.5 at week 52 in the TNFi group. Similarly, SJC decreased over time, with a mean absolute change of -1.9 at week 12 and -2.1 at week 52 in the TREMFYA group and of -1.2 at week 12 and -2.4 at week 52 in the TNFi group.
- Dactylitis prevalence declined in both groups, with complete resolution occurring at weeks 12, 24, and 52, respectively, in 46.2% (6/13), 80.0% (8/10), and 71.4% (5/7) of TREMFYA-treated patients and 88.9% (8/9), 75.0% (6/8), and 100.0% (5/5) of TNFi-treated patients. For details of MDA, remission and LDA, dactylitis, mean LEI, and HAQ scores, see Table: Treatment Effectiveness of Second-Line TREMFYA and Second-Line TNFi through Week 52.
Treatment Effectiveness of Second-Line TREMFYA and Second-Line TNFi through Week 521
|
|
|
|
|
|---|
|
|
|
|
|
|
|
|
|---|
MDAa (%)
| 18.2 (n=4)
| 13.3 (n=2)
| 27.0 (n=20)
| 24.2 (n=15)
| 41.7 (n=25)
| 32.0 (n=16)
| 52.3 (n=23)
| 33.3 (n=12)
|
Remission and LDA (%)
| 18.8 (n=64)
| 23.5 (n=51)
| 45.1 (n=82)
| 60.0 (n=65)
| 67.2 (n=61)
| 63.0 (n=54)
| 66.7 (n=45)
| 62.2 (n=37)
|
Dactylitis (%)
| 13.5 (n=96)
| 11.7 (n=77)
| 9.6 (n=94)
| 1.7 (n=76)
| 5.6 (n=72)
| 4.9 (n=61)
| 5.9 (n=51)
| 0.0 (n=39)
|
Mean LEI
| 0.7 (n=61)
| 0.7 (n=47)
| 0.7 (n=90)
| 0.7 (n=72)
| 0.4 (n=69)
| 0.5 (n=60)
| 0.5 (n=50)
| 0.4 (n=39)
|
HAQ score (mean)
| 0.8 (n=29)
| 1.0 (n=20)
| 0.9 (n=91)
| 0.9 (n=73)
| 0.8 (n=70)
| 0.9 (n=56)
| 0.8 (n=46)
| 0.8 (n=39)
|
Abbreviations: BSA, body surface area; HAQ, Health Assessment Questionnaire; LDA, low disease activity; LEI, Leeds Enthesitis Index; MDA, minimal disease activity; PGA, Patient’s Global Assessment; SJC, swollen joint count; TJC, tender joint count; TNFi, tumor necrosis factor inhibitor; VAS, Visual Analog Scale. aMDA was achieved if 5 of 7 criteria were met: TJC ≤1, SJC ≤1, BSA ≤3%, patient’s assessment of pain by VAS ≤15 mm, PGA of disease activity by VAS ≤20 mm, HAQ ≤0.5, and tender entheseal points ≤1 (assessed using LEI).
|
- AEs were reported in 35 patients, including 19 (19.4%) patients in the TREMFYA group and 16 (20.8%) patients in the TNFi group.
- Of all reported AEs, 4 (14.8%) events in the TREMFYA group and 7 (31.8%) events in the TNFi group were considered treatment related.
Joven-Ibáñez et al (2025)2 reported results from MANHATTAN study comparing the persistence, effectiveness, and tolerability of second-line SC TREMFYA vs a second-line SC TNFi through week 52 in adult patients with PsA.
Study Design/Methods
- Patients who had previously received TNFi and were switched to either TREMFYA or another TNFi as second-line therapy were included in the study.
- Study endpoints included as follows:
- Treatment persistence analyzed by Kaplan-Meier curves
- Percentage of patients achieving MDA
- Psoriatic body surface area (BSA)
- Mean change in TJC
- Mean change in SJC
- The study design and visit schedule are summarized in Figure: MANHATTAN Study Design and Visit Schedule.
Results
Selected Baseline Demographic Characteristics2
|
|
|
|---|
Male, n (%)
| 31 (40.3)
| 31 (50.0)
|
BMI (kg/m2), mean (SD)
| 28.2 (6.6)
| 27.3 (5.7)
|
PsA characteristics, n (%)
|
Age at PsA diagnosis (years), mean (SD)
| 43.9 (11.9)
| 44.7 (11.9)
|
Active PsO
| 51 (66.2)
| 29 (47.5)
|
Dactylitis
| 12 (15.8) (n=76)
| 11 (18.0) (n=61)
|
Enthesitis
| 16 (21.1) (n=76)
| 23 (37.1) (n=61)
|
TJC,mean (SD)
| 6.0 (6.1) (n=60)
| 5.5 (5.8) (n=50)
|
SJC, mean (SD)
| 3.5 (4.8) (n=60)
| 2.9 (4.0) (n=50)
|
DAPSA,mean (SD)
| 23.0 (13.2) (n=51)
| 21.2 (12.3) (n=39)
|
BSA, mean (SD)
| 4.0 (5.2)
| 1.9 (4.1)
|
Abbreviations: BMI, body mass index; BSA, body surface area; DAPSA, Disease Activity in Psoriatic Arthritis; PsA, psoriatic arthritis; PsO, psoriasis; SD, standard deviation; SJC, swollen joint count; TJC, tender joint count; TNFi, tumor necrosis factor inhibitor.
|
- The most common second-line TNFi was etanercept (46.8%) followed by adalimumab (25.8%).
- The use of concomitant conventional disease-modifying antirheumatic drug (DMARDs) was reported in 41.6% and 41.9% of patients in the second-line TREMFYA and second-line TNFi groups, respectively.
- Persistence at week 52 was higher in the TREMFYA group (85.3%) compared to TNFi group (73.5%); see Figure: KM Plot of Second-Line Treatment (TREMFYA or TNFi) Persistence up to Week 52.
KM Plot of Second-Line Treatment (TREMFYA or TNFi) Persistence up to Week 522

Abbreviations: GUS, guselkumab; KM, Kaplan-Meier; TNFi, tumor necrosis factor inhibitor.
TJC and SJC in Second-Line Treatment (TREMFYA or TNFi) at Weeks 12, 24, and 522
|
|
|
|---|
TJC
|
Week 12
| -2.7
| -2.2
|
Week 24
| -3.3
| -3.5
|
Week 52
| -3.2
| -3.8
|
SJC
|
Week 12
| -2.0
| -1.6
|
Week 24
| -1.9
| -2.4
|
Week 52
| -2.2
| -3.1
|
Abbreviations: SJC, swollen joint count; TJC, tender joint count; TNFi, tumor necrosis factor inhibitor.
|
Retrospective Studies
Walsh et al (2024)3 compared the on-label treatment persistence in a real-world setting in patients with PsA treated with SC TREMFYA vs SC TNFi using the IQVIA PharMetrics® Plus database through 12 months.
Study Design/Methods
- Inclusion criteria:
- Adult patients with PsA who received an index biologic (ie, SC TREMFYA 100 mg at baseline, week 4, and every 8 weeks [Q8W] or first SC TNFi [adalimumab, certolizumab pegol, etanercept, or golimumab]) between July 14, 2020, and
March 31, 2022, were included. - The index date was defined as the date of first claim for TREMFYA or TNFi.
- The baseline period was defined as 12 months before the index date in which the patient had a diagnosis for PsA based on ≥2 claims for PsA ≥30 days apart and ≥1 prescription claim for a PsA-related medication.
- Patients were identified as either biologic-naïve or biologic-experienced based on prior biologic DMARD (bDMARD) use (other than SC TREMFYA, TNFi, or IV TNFi) during the 12-month baseline period.
- Exclusion criteria:
- Patients had received ≥1 claim for any of the studied drugs at any time during the period of continuous eligibility before the index date.
- Patients initiated >1 index biologic on the index date or had ≥1 diagnosis for other potentially confounding rheumatic diseases (as listed by the authors) in the baseline period.
- In the primary analysis, on-label treatment persistence was defined as the absence of treatment discontinuation (based on a gap of 112 days for TREMFYA or 56 days for an TNFi) or any dose escalation/reduction during follow-up.
- Sensitivity analyses were done for on-label persistence, defined as follows:
- First sensitivity analysis: absence of treatment discontinuation based on a gap of 56 days for TREMFYA or 28 days for an TNFi.
- Second sensitivity analysis: absence of treatment discontinuation for a fixed 112 days to evaluate persistence based on the same gap definition for all index biologics.
- Cox proportional hazard models were used to compare the risk of discontinuation between the standardized mortality ratio-weighted treatment cohorts (TREMFYA and TNFi groups).
Results
Baseline Characteristics
- In the TREMFYA group (N=526), 48.5% were biologic naïve and in the TNFi group (N=1953: adalimumab, n=1339; etanercept, n=400; certolizumab pegol, n=159; golimumab, n=55), 87.9% were biologic-naïve during the 12-month baseline period.
- After implementation of treatment weighting, baseline demographic and clinical characteristics were comparable (except for prior bDMARD use during the baseline period [51.5% in the SC TREMFYA vs 16.7% in the SC TNFi cohort]) across the TREMFYA and TNFi groups. See Table: Select Demographics and Baseline Characteristics for Weighted Cohort in the 12-Month Baseline Period.
Select Demographics and Baseline Characteristics for Weighted Cohort in the 12-Month Baseline Period3,a
|
|
|
|
|---|
Age at index date, years, mean±SD; median
| 49.8±11.7; 50.7
| 49.2±11.6; 50.3
| 5.2
|
Time between latest observed PsA diagnosis and index date, months, mean±SD (median)
| 1.4±1.7 (0.8)
| 1.2±1.6 (0.7)
| 9.6
|
Baseline Quan-CCI score, mean±SD (median)
| 0.6±1.4 (0.0)
| 0.6±1.4 (0.0)
| 0.6
|
Any prior PsA treatment, n (%)
| 385 (73.2)
| 1012 (51.8)
| 45.3
|
bDMARDsb
| 271 (51.5)
| 327 (16.7)
| 78.9
|
1
| 228 (84.1)
| 302 (92.4)
| 64.3
|
≥2
| 43 (15.9)
| 25 (7.6)
| 34.3
|
csDMARDsc
| 118 (22.4)
| 471 (24.1)
| 4.0
|
tsDMARDsd
| 95 (18.1)
| 359 (18.4)
| 0.8
|
Abbreviations: bDMARD, biologic disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; CTLA-4, cytotoxic T-lymphocyte associated antigen 4; IL, interleukin; JAK, Janus kinase; PsA, psoriatic arthritis; Quan-CCI, Quan-Charlson comorbidity index; SD, standard deviation; TNFi, tumor necrosis factor inhibitor; tsDMARD, targeted synthetic disease-modifying antirheumatic drug. aPropensity score weighting based on the standardized mortality ratio weighting approach was used to adjust for differences in baseline characteristics between the SC TREMFYA and SC TNFi groups. Weights were estimated using a multivariable logistic regression model. Baseline covariates included all demographic and clinical characteristics reported in this table with the exception of baseline use of bDMARDs, which was included in the adjusted Cox proportional hazard models. bIL-17A inhibitors (secukinumab and ixekizumab), IL-12/23 inhibitor (ustekinumab), anti-CTLA-4 agent (abatacept), and IL-23p19-subunit inhibitor (risankizumab). The proportion of patients with 1 and ≥2 bDMARDs is reported among those with any bDMARD use. cMethotrexate, leflunomide, cyclosporine, mycophenolate, and azathioprine. dApremilast, deucravacitinib, and JAK inhibitors (upadacitinib, baricitinib, and tofacitinib).
|
Treatment Persistence
- In the TREMFYA vs TNFi group, the mean follow-up time was 12.3 vs 12.4 months and the proportion of PsA patients persistent on treatment after 12 months was 72% vs 44%, respectively.
- In the primary analysis, the TREMFYA group was 3 times more likely to persist on treatment at 12 months compared with the TNFi group (hazard ratio [HR], 2.97; 95% confidence interval [CI], 2.36-3.74; P<0.001).
- The median time to discontinuation was not reached in the TREMFYA group and 8.9 months in the TNFi group.
- On-label persistence at 3, 6, 9, and 12 months is summarized in Table: Analysis of On-Label Persistence through 12 Months in the Weighted TREMFYA and TNFi Groups.
Analysis of On-Label Persistence through 12 Months in the Weighted TREMFYA and TNFi Groups3,7,a
|
|
|
|
|
|---|
Primary analysis
|
Patients at risk,d n (%)
|
3 months
| 368 (70.0)
| 1051 (53.8)
| 3.41 (2.41-4.80)
| <0.001e
|
6 months
| 263 (50.0)
| 744 (38.1)
| 3.30 (2.51-4.33)
| <0.001e
|
9 months
| 155 (29.5)
| 452 (23.1)
| 3.06 (2.41-3.88)
| <0.001e
|
12 months
| 84 (16.0)
| 299 (15.3)
| 2.97 (2.36-3.74)
| <0.001e
|
KM persistence, % (95% CI)
|
3 months
| 91.2 (82.8-95.6)
| 77.3 (73.1-80.9)
| -
| <0.001f
|
6 months
| 84.1 (76.7-89.4)
| 61.6 (56.8-66.1)
| -
| <0.001f
|
9 months
| 75.9 (68.3-81.9)
| 50.0 (44.4-55.3)
| -
| <0.001f
|
12 months
| 71.5 (63.2-78.3)
| 43.7 (37.3-49.8)
| -
| <0.001f
|
Sensitivity analysis 1
|
Patients at risk,d n (%)
|
3 months
| 352 (66.9)
| 996 (51.0)
| 2.73 (2.04-3.65)
| <0.001e
|
6 months
| 251 (47.7)
| 685 (35.1)
| 2.49 (1.98-3.13)
| <0.001e
|
9 months
| 144 (27.4)
| 388 (19.9)
| 2.51 (2.04-3.07)
| <0.001e
|
12 months
| 76 (14.4)
| 242 (12.4)
| 2.41 (1.98-2.92)
| <0.001e
|
KM persistence, % (95% CI)
|
3 months
| 87.1 (79.6-92.0)
| 72.3 (67.9-76.1)
| -
| <0.001f
|
6 months
| 76.4 (69.3-82.0)
| 55.0 (49.9-59.7)
| -
| <0.001f
|
9 months
| 66.7 (59.2-73.2)
| 41.5 (35.6-47.3)
| -
| <0.001f
|
12 months
| 59.2 (50.4-67.0)
| 33.5 (26.6-40.4)
| -
| <0.001f
|
Sensitivity analysis 2
|
Patients at risk,d n (%)
|
3 months
| 368 (70.0)
| 1106 (56.6)
| 2.55 (1.79-3.63)
| <0.001e
|
6 months
| 263 (50.0)
| 803 (41.1)
| 2.54 (1.92-3.35)
| <0.001e
|
9 months
| 155 (29.5)
| 493 (25.2)
| 2.38 (1.86-3.03)
| <0.001e
|
12 months
| 84 (16.0)
| 329 (16.8)
| 2.35 (1.86-2.97)
| <0.001e
|
KM persistence, % (95% CI)
|
3 months
| 91.2 (82.8-95.6)
| 82.6 (78.5-86.0)
| -
| <0.001f
|
6 months
| 84.1 (76.7-89.4)
| 68.7 (64.1-72.9)
| -
| <0.001f
|
9 months
| 75.9 (68.3-81.9)
| 58.9 (53.6-63.8)
| -
| <0.001f
|
12 months
| 71.5 (63.2-78.3)
| 52.1 (46.0-57.8)
| -
| <0.001f
|
Abbreviations: bDMARD, biologic disease-modifying antirheumatic drug; CI, confidence interval; KM, Kaplan-Meier; TNFi, tumor necrosis factor inhibitor. aPropensity score weighting based on the standardized mortality ratio weighting approach was used to adjust for differences in baseline characteristics between the TREMFYA and TNFi groups. Weights were estimated using a multivariable logistic regression model. Baseline covariates included all demographic and clinical characteristics with the exception of baseline use of bDMARDs, which was included in the adjusted Cox proportional hazard models. bCox proportional hazard models were used to compare the risk of discontinuation between the weighted TREMFYA and TNFi groups. Models were adjusted for baseline use of bDMARDs. cDenotes statistical significance based on a threshold of P<0.05. dPatients at risk of having the event are patients who have not had the event and have not been lost to follow-up at that point in time. eP values were determined by using Chi-square test. fP values were determined by using log-rank test.
|
- In sensitivity analysis 1, the TREMFYA group was 2.4 times more likely to persist on treatment at 12 months compared with the TNFi group (HR, 2.41; 95% CI, 1.98-2.92; P<0.001).3,7
- The median time to discontinuation was 18.4 months in the TREMFYA group and 6.9 months in the TNFi group.3
- In sensitivity analysis 2, the TREMFYA group was 2.4 times more likely to persist on treatment at 12 months compared with the TNFi group (HR, 2.35; 95% CI, 1.86-2.97; P<0.001).3,7
- The median time to discontinuation was not reached in the TREMFYA group and 13.8 months in the TNFi group.3
Mease et al (2026)4 compared the on-label treatment persistence over 24 months among adult patients with active PsA initiating SC TREMFYA vs SC TNFi in real-world clinical practice.
Study Design/Methods
- Data from the IQVIA PharMetrics® plus United States (US) claims database between January 2011 and June 2023 were utilized.
- Adults with active PsA were identified from US claims data based on initiation of a single index therapy during the intake period, ≥12 months of continuous health plan eligibility before the index date, and ≥2 PsA diagnosis claims ≥30 days apart during baseline or on the index date.
- Patients who received an index biologic (ie, SC TREMFYA 100 mg at baseline, week 4, and Q8W or the first SC TNFi [adalimumab, certolizumab pegol, etanercept, or golimumab]) were included in the study.
- Patients should not have a baseline diagnosis indicating alternative inflammatory conditions to ensure treatment use for PsA.
- Patients received only 1 index agent on the index date and had not received any diagnosis for other potentially confounding rheumatic diseases (as listed by the authors) during the baseline period.
- In the primary analysis, on-label treatment persistence was defined as the absence of treatment discontinuation (based on a gap of 112 days for TREMFYA or 56 days for TNFi) or any dose escalation/reduction during follow-up.
- Sensitivity analyses were performed for on-label persistence, which was defined as follows:
- Therapy exposure gap utilized the Food and Drug Administration (FDA)-approved dosing regimen for each index agent (a gap of 56 days for TREMFYA and 28 days for TNFis).
- Fixed therapy exposure gap utilized a fixed gap of 112 days to define discontinuation for all index agents.
Results
Baseline Characteristics
- A total of 804 and 2490 patients were included in the TREMFYA and TNFi cohorts respectively. In the TREMFYA cohort, 361 (44.9%) and 443 (55.1%) patients were biologic naïve and biologic experienced, respectively. In the TNFi cohort, 2171 (87.2%) and 319 (12.8%) patients were biologic naïve and biologic experienced, respectively.
- The mean follow-up duration was 15.4 months and 15.2 months in the TREMFYA and TNFi cohorts, respectively.
- The selected baseline characteristics are summarized in Table: Selected Weighted Baseline Demographics and Clinical Characteristics.
Selected Weighted Baseline Demographics and Clinical Characteristics4
|
|
|
|---|
Age at index date, years, mean (SD)
| 49.4 (11.2)
| 49.5 (11.2)
|
Female, n (%)
| 485 (60.3)
| 1502 (60.3)
|
Time between latest observed PsA diagnosis to index date, months, mean (SD) [median]c
| 1.2 (1.4) [0.7]
| 1.2 (1.6) [0.7]
|
Any prior PsA treatment, n (%)
| 572 (71.2)
| 1772 (71.2)
|
bDMARD used
| 383 (47.6)
| 350 (14.0)
|
csDMARD usee
| 180 (22.4)
| 1202 (48.3)
|
tsDMARD usef
| 170 (21.1)
| 583 (23.4)
|
JAK inhibitors
| 33 (4.1)
| 103 (4.1)
|
Abbreviations: bDMARD, biologic disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; IL, interleukin; JAK, Janus kinase; PsA, psoriatic arthritis; SD, standard deviation; TNFi, tumor necrosis factor inhibitor; tsDMARD, targeted synthetic disease-modifying antirheumatic drug. aPropensity matching used. bOf note, the number of patients reported in this weighted population represents the sum of weights for the corresponding nonweighted patients, rounded to the nearest integer. The proportions displayed were calculated prior to the rounding and may be slightly different than if they were calculated on the basis of rounded numbers. cIncluded PsA diagnoses on the index date. dIL-17A inhibitor (secukinumab and ixekizumab), IL-12/23 inhibitor (ustekinumab), IL-23p19 subunit inhibitor (risankizumab), CTLA-4 inhibitor (abatacept). eMethotrexate, leflunomide, azathioprine, mycophenolate, cyclosporine. fApremilast and JAK inhibitors (tofacitinib, upadacitinib, baricitinib).
|
Treatment Persistence
- At 24 months, persistence with on-label treatment was observed in 45.5% of patients in the TREMFYA group vs 28.5% of patients in the TNFi group (P<0.001).
- The median time to discontinuation in the TREMFYA vs TNFi group was 22.0 vs 9.2 months, respectively.
- In the overall cohort, patients in the TREMFYA group were 2.24 times more likely to remain persistent with on-label treatment through 24 months compared with those in the TNFi group (Overall cohort: HR, 2.24; 95% CI, 1.90-2.64; P<0.001 vs therapy exposure gap: HR, 1.90; 95% CI, 1.65-2.19; P<0.001 vs fixed gap: HR, 1.80; 95% CI, 1.52-2.13; P<0.001).
- On-label treatment persistence is summarized in Table: Primary Analysis of On-Label Persistence in Weighted TREMFYA and TNFi Cohort
Primary Analysis of On-Label Persistence in Weighted TREMFYA and TNFi Cohort4
|
|
|
|
|---|
|
|
|
|---|
Overall TREMFYA (N=804) TNFi (N=2490)
| 65.9 (59.2-71.8) 43.8 (39.3-48.2)
| 58.1 (49.5-65.7) 35.4 (30.0-40.8)
| 45.5 (26.9-62.1) 28.5 (21.5-35.9)
|
P-value
| <0.001
| <0.001
| <0.001
|
Biologic-naїve TREMFYA (n=361) TNFi (n=2171)
| 73.1 (63.2-80.7) 43.8 (38.0-49.4)
| 62.9 (50.2-73.1) 35.3 (28.4-42.3)
| 48.9 (24.9-69.3) 28.4 (19.6-37.9)
|
P-value
| <0.001
| <0.001
| <0.001
|
Biologic-experienced TREMFYA (n=443) TNFi (n=319)
| 57.7 (47.1-67.0) 40.3 (27.7-52.4)
| 50.6 (36.3-63.2) 31.1 (15.3-48.5)
| 39.5 (3.6-63.0) 23.3 (5.2-48.2)
|
P-value
| <0.001
| <0.001
| <0.001
|
Abbreviations: CI, confidence interval; KM, Kaplan-Meier; TNFi, tumor necrosis factor inhibitor.
|
Network Meta-analysis
Mease et al (2021)5 and (2023)6 conducted a Bayesian NMA to indirectly compare the treatment effect of SC TREMFYA with other targeted therapies for PsA, including TNFis (IV: golimumab, infliximab, adalimumab, etanercept, and certolizumab pegol), on joint and skin efficacy outcomes and safety in adults (≥18 years of age) with active PsA.
Study Design/Methods
- A systematic literature review was conducted to identify randomized controlled trials (the original search was conducted in October 2018 and subsequently updated in January 2020 to expand the comparator scope) assessing the use of targeted synthetic DMARDs (tsDMARDs) and bDMARDs in adults with active PsA.5
- The NMA was updated up to February 2021 and again in July 2021 to include new data and new agents.6
- The Bayesian NMA was performed to compare treatments on American College of Rheumatology (ACR) 20/50/70 response, change from baseline in van der Heijde-Sharp (vdH-S) score, Psoriasis Area and Severity Index (PASI) 75/90/100 response, and serious adverse events (SAEs).
- From the primary assessment timepoint of each trial, ACR and PASI data were included, which varied from 12 to 24 weeks.
- vdH-S data was included from the 24-week timepoint.
- Regarding SAEs, the latest placebo-controlled timepoint was utilized in this analysis (up to 24 weeks).
- A multinomial probit NMA model for ordinal outcomes was used to compare interventions for ACR and PASI; dichotomous outcomes were used for SAEs; and continuous outcomes were used for vdH-S score.
- Treatment effects for ordinal and dichotomous outcomes were modeled on the probit and log-odds ratio scales, respectively.
- These treatment effects were transformed to relative risks using the unweighted averages of trial placebo responses.
- For continuous outcomes, treatment effects were modeled and reported on the mean difference scale.
- Treatments evaluated pertaining to TREMFYA 100 mg SC Q8W compared with the following TREMFYA dosing regimen and the TNFis6,8:
- TREMFYA 100 mg SC every 4 weeks
- IV TNFis (golimumab 2 mg weight-based [WT] and infliximab 5 mg WT)
- SC TNFis (adalimumab 40 mg, etanercept 25 mg, golimumab 50 mg, and certolizumab 400 mg and 200 mg)
Results
- A total of 33 trials (87 citations) evaluating all doses of tsDMARDs and bDMARDs approved by either the FDA or European Medicines Agency (EMA) for the treatment of active PsA were included in the NMA.
- For results specific to multi-ACR20 response, multi-PASI 90 response, vdH-S score, and SAEs, respectively, see:
Forest Plot with Pairwise Comparisons of TREMFYA Q8W vs Comparators for Multi-ACR20 Response8
Abbreviations: ACR, American College of Rheumatology; Crl, credible interval; IL-23i, interleukin-23 inhibitor; IV, intravenous; Q4W, every 4 weeks; Q8W, every 8 weeks; RR, relative risk; SC, subcutaneous; TNFi, tumor necrosis factor inhibitor; WT, weight-based.
Forest Plot with Pairwise Comparisons of TREMFYA Q8W vs Comparators for Multi-PASI 90 Response8

Abbreviations: Crl, credible interval; IL-23i, interleukin-23 inhibitor; IV, intravenous; PASI, Psoriasis Area and Severity Index; Q4W, every 4 weeks; Q8W, every 8 weeks; RR, relative risk; SC, subcutaneous; TNFi, tumor necrosis factor inhibitor; WT, weight-based.
Forest Plot with Pairwise Comparisons of TREMFYA Q8W vs Comparators for vdH-S Score8

Abbreviations: Crl, credible interval; IL-23i, interleukin-23 inhibitor; IV, intravenous; MD, mean difference; Q4W, every 4 weeks; Q8W, every 8 weeks; RR, relative risk; SC, subcutaneous; TNFi, tumor necrosis factor inhibitor; vdH-S, van der Heijde-Sharp; WT, weight-based.
Forest Plot with Pairwise Comparisons of TREMFYA Q8W vs Comparators for SAEs8

Abbreviations: Crl, credible interval; IL-23i, interleukin-23 inhibitor; IV, intravenous; Q4W, every 4 weeks; Q8W, every 8 weeks; RR, relative risk; SAE, serious adverse event; SC, subcutaneous; TNFi, tumor necrosis factor inhibitor; WT, weight-based.
Literature Search
A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 07 September 2026.
| 1 | González-Molina R, Joven-Ibáñez B, Llanes Gómez M, et al. Effectiveness and tolerability of guselkumab or TNF inhibitors as second-line treatment after receiving a TNF inhibitor as first-line therapy to treat active psoriatic arthritis: 52-week interim data from the Manhattan study. Poster presented at: American College of Rheumatology (ACR) Convergence 2025; October 24-29, 2025; Chicago, IL. |
| 2 | Joven-Ibáñez B, González-Molina MR, Hernández Hernández MV, et al. One year persistence and effectiveness of guselkumab or TNFi as second-line treatment after receiving a TNFi as first-line therapy to treat active psoriatic arthritis: MANHATTAN study. Poster presented at: European Alliance of Associations for Rheumatology (EULAR); June 11-14, 2025; Barcelona, Spain. |
| 3 | Walsh JA, Lin I, Zhao R, et al. Comparison of real-world on-label treatment persistence in patients with psoriatic arthritis receiving guselkumab versus subcutaneous tumor necrosis factor inhibitors. Drugs Real World Outcomes. 2024;11(3):487-499. |
| 4 | Mease PJ, Walsh JA, Fitzgerald TP, et al. On-label treatment persistence through 24 months among patients with active psoriatic arthritis initiating guselkumab or subcutaneous tumor necrosis factor inhibitors. Rheumatol Ther. 2026;13(1):115-134. |
| 5 | Mease PJ, McInnes IB, Tam LS, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology (Oxford). 2021;60(5):2109-2121. |
| 6 | Mease PJ, McInnes IB, Tam LS, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis. Rheumatology (Oxford). 2023;62(4):1417-1425. |
| 7 | Walsh JA, Lin I, Zhao R, et al. Supplement to: Comparison of real-world on-label treatment persistence in patients with psoriatic arthritis receiving guselkumab versus subcutaneous tumor necrosis factor inhibitors. Drugs Real World Outcomes. 2024;11(3):487-499. |
| 8 | Mease PJ, McInnes IB, Tam LS, et al. Supplement to: Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis. Rheumatology (Oxford). 2023;62(4):1417-1425. |